Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG-102-12
- Development stage
- Discontinued
- Lead developer
- Cells & Genes Biotech
01
Overview
CG-102-12 is an investigational drug candidate that acts as a glypican 3 (GPC3) inhibitor. It was initially developed by Sethkin Biotechnology (Shanghai) and is being studied for the treatment of hepatocellular carcinoma, a primary form of liver cancer. GPC3 is a cell surface heparan sulfate proteoglycan highly expressed in hepatocellular carcinoma and implicated in tumor growth and progression, making it an attractive therapeutic target. The precise modality or molecular format of CG-102-12 has not been disclosed in public sources, but its mechanism involves inhibition or modulation of GPC3 function to exert antitumor effects[1][2].
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on CG-102-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG-102-12.